GMAB News and Press, Genmab A/S From 09/27/22

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and ...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q2 2022 Earnings Call Aug 10, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

Genmab A/S (GMAB) Q2 2022 Results Conference Call August 10, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Of...

Genmab A/S press release ( GMAB ): Q2 GAAP EPS of DKK28.66. Revenue of DKK3.16B (+60.4% Y/Y). Shares +1.4% . On Aug. 08, the company raised its FY22 guidance . For further details see: Genmab A/S GAAP EPS of DKK28.66, revenue of DKK3.16B

Genmab ( GMAB ) improves FY 2022 guidance expects its 2022 revenue to be in the range of DKK 12,000M – 13,000M, an increase to the previous guidance of DKK 11,000M – 12,000M, driven primarily by the continued strong growth of DARZALEX net sales as well as the pos...

Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody ® technology platform to develop novel monospecific antibodies First mono...

Cancer immunotherapy developer Immatics ( NASDAQ: IMTX ) is up 17% in Tuesday afternoon trading on volume that is ( IMTX ) four times higher than the normal daily average. Average volume for the stock is 146,757. As of 230p ET, ~586K shares had traded hands. Th...

Genmab ( GMAB ) said global net sales of Darzalex reported by Johnson & Johnson ( JNJ ) rose 38.6% to $1.99B in Q2. Net trade sales were USD 1.02B in the U.S. and $965M in the rest of the world. Genmab receives royalties on the worldwide net sal...

Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for ...